A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Rinvecalinase alfa (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms REDUX
- Sponsors DiaMedica Therapeutics
- 26 Jun 2024 Results presented in the DiaMedica Therapeutics Media Release.
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 14 Mar 2022 According to a DiaMedica Therapeutics media release, interim data were presented at the American Society of Nephrology annual Kidney Week meeting in November 2021.